CD8A and COVID-19: This is particularly relevant as human studies have identified a CD8+ T cell response against SARS-CoV-2 Nucleocapsid (N105-113) epitope, presented by HLA-B*07:02, in 80% of naïve participants and is significantly associated with mild COVID-19 (73–76).